Page 1362 - Williams Hematology ( PDFDrive )

1336 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1337

340. Barbui T, Thiele J, Passamonti F, et al: Survival and disease progression in essential 372. Filho FDR, Ferreira VDA, Mendes FDO, et al: Bone marrow fibrosis (pseudo-myelofi-
thrombocythemia are significantly influenced by accurate morphologic diagnosis: An brosis) in kala-azar. Rev Soc Bras Med Trop 33:363, 2000.
international study. J Clin Oncol 29:3179, 2011. 373. Seelen MA, de Meijer PH, Posthuma EF, Meinders AE: Myelofibrosis and idiopathic
341. Thiele J, Kvasnicka HM, Zankovich R, Diehl V: Relevance of bone marrow features thrombocytopenic purpura. Ann Hematol 75:129, 1997.
in the differential diagnosis between essential thrombocythemia and early stage idio- 374. Chang JC, Naqvi T: Thrombotic thrombocytopenic purpura associated with bone mar-
pathic myelofibrosis. Haematologica 85:1126, 2000. row metastasis and secondary myelofibrosis in cancer. Oncologist 8:375, 2003.
342. Hasselbach H, Jans H, Nielsen PL: A distinct subtype of idiopathic myelofibrosis with 375. Hatake K, Ohtsuki T, Uwai M, et al: Tretinoin induces bone marrow collagenous fibro-
bone marrow features mimicking hairy cell leukemia. Evidence of an autoimmune sis in acute promyelocytic leukemia. Br J Haematol 93:646, 1996.
pathogenesis. Am J Hematol 25:225, 1979. 376. Labotka RJ, Morgan RR: Myelofibrosis with neuroblastoma. Med Pediatr Oncol 10:21,
343. O’Reilly RA: Splenomegaly at a United States County Hospital: Diagnostic evaluation of 1982.
170 patients. Am J Med Sci 312:160, 1996. 377. Karcher DS, Pearson CE, Butler WM, et al: Giant lymph node hyperplasia involving
344. Pullarkat V, Bass RD, Gong JZ, et al: Primary autoimmune myelofibrosis: Definition of the thymus with associated nephrotic syndrome and myelofibrosis. Am J Clin Pathol
a distinct clinicopathologic syndrome. Am J Hematol 72:8, 2003. 77:100, 1982.
345. Harrison JS, Corcoran KE, Joshi D, et al: Peripheral monocytes and CD4+ cells are 378. Kamien B, Harris L: Twin troubles—Rickets causing myelofibrosis. J Paediatr Child
potential sources for increased circulating levels of TGF-beta and substance P in auto- Health 43:573, 2007.
immune myelofibrosis. Am J Hematol 81:51, 2006. 379. Stéphan JL, Galambrun C, Dutour A, Freycon F: Myelofibrosis: An unusual presenta-
346. Popat U, Frost A, Liu E, et al: High levels of circulating CD34 cells, dacryocytes, clonal tion of vitamin D-deficient rickets. Eur J Pediatr 158:828, 1999.
hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid meta- 380. Gruner BA, DeNapoli TS, Elshihabi S, et al: Anemia and hepatosplenomegaly as pre-
plasia from secondary myelofibrosis associated with pulmonary hypertension. Blood senting features in a child with rickets and secondary myelofibrosis. J Pediatr Hematol
107:3486, 2006. Oncol 25:813, 2003.
347. Fortunato A, Mazzone A, Ricevuti G: Myelofibrosis caused by cancer: Presentation of a 381. Razali NN, Hwu TT, Thilakavathy K: Phosphate homeostasis and genetic mutations of
clinical case with a very difficult diagnosis. Minerva Med 76:1051, 1985. familial hypophosphatemic rickets. J Pediatr Endocrinol Metab 2015. [Epub ahead of print]
348. Yablonski-Peretz T, Sulkes A, Polliack A, et al: Secondary myelofibrosis with metastatic 382. Sartoris DJ, Resnick D: Myelofibrosis arising in treated histiocytosis X. Eur J Pediatr
breast cancer simulating agnogenic myeloid metaplasia: Report of a case and review of 144:200, 1985.
the literature. Med Pediatr Oncol 13:92, 1985. 383. Fukuno K, Tsurumi H, Yoshikawa T, et al: A variant of acute promyelocytic leukemia
349. Ishimura J, Fukushi M: Scintigraphic evaluation of secondary myelofibrosis associated with marked myelofibrosis. Int J Hematol 74:322, 2001.
with prostatic cancer before hormonal therapy. Clin Nucl Med 15:330, 1990. 384. Mori A, Wada H, Okada M, et al: Acute promyelocytic leukemia with marrow fibro-
350. Smart HE, Canney PA, Kerr DJ: Myelofibrosis associated with metastatic seminoma. sis at initial presentation. Possible involvement of transforming growth factor-beta(1).
Clin Oncol 4:132, 1992. Acta Haematol 103:220, 2000.
351. Takahashi T, Akihama T, Yamaguchi A, et al: Lysozyme secreting tumor: A case of gas- 385. Shah-Reddy I, Subramanian L, Narang S: Myelofibrosis and true histiocytic lymphoma.
tric cancer associated with myelofibrosis due to disseminated bone marrow metastasis. Tumori 71:509, 1985.
Jpn J Med 26:58, 1987. 386. Jennings WH, Li CY, Kiely JM: Concomitant myelofibrosis with agnogenic myeloid
352. Rubins JM: The role of myelofibrosis in malignant leukoerythroblastosis. Cancer metaplasia and malignant lymphoma. Mayo Clin Proc 58:617, 1983.
51:308, 1983. 387. Epstein RJ, Joshua DE, Kronenberg H: Idiopathic myelofibrosis complicated by lym-
353. Hashim MSK, Kordofani AYA, El Dabi MA: Tuberculosis and myelofibrosis in children. phoma: Report of two cases. Acta Haematol 73:40, 1985.
Ann Trop Paediatr 17:61, 1997. 388. Kaufman S, Iuclea S, Reif R: Idiopathic myelofibrosis complicated by chronic lymphatic
354. Viallard J-F, Parrens M, Boiron J-M, et al: Reversible myelofibrosis induced by tubercu- leukaemia. Clin Lab Haematol 9:81, 1987.
losis. Clin Infect Dis 34:1641, 2002. 389. Nieto LH, Raya Sánchez JM, Arguelles HA, et al: A case of chronic lymphocytic leu-
355. Sawers AH, Davson J, Braganza J, et al: Systemic mastocytosis, myelofibrosis and portal kemia overwhelmed by rapidly progressive idiopathic myelofibrosis. Haematologica
hypertension. J Clin Pathol 35:617, 1982. 85:973, 2000.
356. Reisberg IR, Oyakawa S: Mastocytosis with malabsorption, myelofibrosis, and massive 390. Subramanian VP, Gomez GA, Han T, et al: Coexistence of myeloid metaplasia with
ascites. Am J Gastroenterol 82:54, 1987. myelofibrosis and hairy-cell leukemia. Arch Intern Med 145:164, 1985.
357. Kanbe N, Kurosawa M, Nagata H, et al: Production of fibrogenic cytokines by cord 391. Sotlar K, Bache A, Stellmacher F, et al: Systemic mastocytosis associated with chronic
blood-derived cultured human mast cells. J Allergy Clin Immunol 106:S85, 2000. idiopathic myelofibrosis: A distinct subtype of systemic mastocytosis associated with a
358. Berton A, Levi-Schaffer F, Emonard H, et al: Activation of fibroblasts in collagen lattices clonal hematological non-mast cell lineage disorder carrying the activating point muta-
by mast cell extracts: A model of fibrosis. Clin Exp Allergy 30:485, 2000. tions KITD816V and JAK2V617F. J Mol Diagn 10:58, 2008.
359. Brenner B, Green J, Rosenbaum H, et al: Severe pancytopenia due to marked marrow 392. Ji SQ, Zhu M, Wang YZ: Primary macroglobulinemia with myelofibrosis: Report of a
fibrosis associated with angioimmunoblastic lymphadenopathy. Acta Haematol 74:43, case. Chin Med J 100:83, 1987.
1985. 393. Humphrey CA, Morris TC: The intimate relationship of myelofibrosis and myeloma:
360. Varma N, Vaiphei K, Varma S: Angiosarcoma presenting with leucoerythroblastic Effect of therapy. Br J Haematol 73:269, 1989.
anaemia bone marrow fibrosis and massive splenomegaly. Br J Haematol 110:503, 2000. 394. Meerkin D, Ashkenazi Y, Gottschalk-Sabag S, Hershko C: Plasma cell dyscrasia with
361. Meckenstock G, Wehmeier A, Schaefer HE, et al: Lymphoid myelofibrosis associated myelofibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia.
with high grade B cell lymphoma of the liver. Leuk Lymphoma 26:197, 1997. Cancer 73:625, 1994.
362. Abe Y, Ohshima K, Shiratsuchi M, et al: Cytotoxic T-cell lymphoma presenting as sec- 395. Kakkar N, Vashishta RK, Banerjee AK, et al: Primary pulmonary malignant teratoma
ondary myelofibrosis with high levels of PDGF and TGF-β. Eur J Haematol 66:210, with yolk sac element associated with hematologic neoplasia. Respiration 63:52, 1996.
2001. 396. Berner Y, Berrebi A: Myeloproliferative disorders and nonmyelomatous paraprotein: A
363. Weirich G, Sandherr M, Fellbaum C, et al: Molecular evidence of bone marrow involve- study of five patients and review of the literature. Isr J Med Sci 22:109, 1986.
ment in advanced case of Tgammadelta lymphoma with secondary myelofibrosis. Hum 397. Ellis JT, Peterson P: Myelofibrosis in the myeloproliferative disorders. Prog Clin Biol Res
Pathol 29:761, 1998. 154:19, 1984.
364. Subramanian R, Basu D, Dutta TK: Significance of bone marrow fibrosis in multiple 398. Najean Y, Rain JD, Dresch C, et al: Risk of leukaemia, carcinoma and myelofibrosis
myeloma. Pathology 39:512, 2007. in P- or chemotherapy-treated patients with polycythaemia vera. Leuk Lymphoma
32
365. Schmidt U, Ruwe M, Leder LD: Multiple myeloma with bone marrow biopsy features 22(Suppl 1):111, 1996.
simulating concomitant chronic idiopathic myelofibrosis. Nouv Rev Fr Hematol 37:159, 399. Najean Y, Rain JD: Treatment of polycythemia vera: Use of P alone or in combination
32
1995. with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of
366. Abildgaard N, Bendix-Hansen K, Kristensen JE, et al: Bone marrow fibrosis and disease age. Blood 89:2319, 1997.
activity in multiple myeloma monitored by the aminoterminal propeptide of procol- 400. Randi ML, Barbone E, Fabris F, et al: Post-polycythemia myeloid metaplasia. J Med
lagen III in serum. Br J Haematol 99:641, 1997. 25:363, 1994.
367. Kim CD, Kim SH, Kim YL, et al: Bone marrow immunoscintigraphy (BMIS): A new 401. Lukowicz DF, Myers TJ, Grasso JA, et al: Sideroblastic anemia terminating in myelofi-
and important tool for the assessment of marrow fibrosis in renal osteodystrophy? Adv brosis. Am J Hematol 13:253, 1982.
Perit Dial 14:183, 1998. 402. Talarico L, Wolf BC, Kumar A, Weintraub LR: Reversal of bone marrow fibrosis and
368. Bachmeyer C, Blum L, Cadranel JF, Delfraissy JF: Myelofibrosis in a patient with pachy- subsequent development of polycythemia vera in patients with myeloproliferative dis-
dermoperiostosis. Clin Exp Dermatol 30:646, 2005. orders. Am J Hematol 30:248, 1989.
369. Nurden AT, Nurden P: The gray platelet syndrome: Clinical spectrum of the disease. 403. Butler MJ, Roda PI, Dorion P: Molecular characterization of a transformation from
Blood Rev 21:21, 2007. primary myelofibrosis into polycythemia vera: A case report. Blood 122:297, 2013.
370. Sadoun A, Lacotte L, Delwail V, et al: Allogeneic bone marrow transplantation for 404. Jallades L, Hayette S, Tigaud I, et al: Emergence of therapy-unrelated CML on a back-
hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant ground of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
19:741, 1997. Leuk Res 32:1608, 2008.
371. Vasquez L, Caballero D, Del Cañizo C, et al: Allogeneic peripheral blood cell transplan- 405. Hussein K, Bock O, Seegers A, et al: Myelofibrosis evolving during imatinib treatment
tation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and
25:217, 2000. JAK2 V617F mutation. Blood 109:4106, 2007.

Kaushansky_chapter 86_p1319-1340.indd 1337 9/18/15 10:24 AM